I’d possibly agree with you if the company was raising capital...

I’d possibly agree with you if the company was raising capital in the US now, but they’re obviously not.

With a compliance listing IHL will be listed on the NASDAQ but with very little, if any liquidity. Remember the only way for shares to end up on their platform is either shareholders sending shares over to the US (unlikely IMO) or via buying in our market (possible, and that would be positive for the share price).

So this is the best of both worlds. The company still has a platform (NASDAQ) to release announcements, promote the clinical trials and build a reputation & profile, but there’s essentially not going to be any liquidity there for now.

In the future when market conditions improve then a placement to the right group of US investors or industry groups will create a liquid market. By then we’d certainly have OSA results and other material news.